FDA approved expanded indication for exenatide
Links shared publicly online about this topic.
- 1,629total visits
FDA approved expanded indication for exenatide
View full resource at endocrinetoday.com
Tags: Diabetes Type 2 Medication, Diabetes Medication, Diet and Nutrition, Exercise and Fitness, FDA, Byetta
Most Recently Shared on November 3, 2009 at 6:06 pm By:
#FDA approved expanded indication for exenatide http://ow.ly/yVIm
FDA Approves Bydureon - The First and Only Once-Weekly Treatment for Type 2 Diabetes
drugs.com — “Bydureon (exenatide) is used to treat type 2 diabetes. Includes Bydureon side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on January 28, 2012 at 1:49 am By:
FDA Approves Bydureon - The First and Only Once-Weekly Treatment for Type 2 Diabetes - http://t.co/Z0Zr4z1L
Medical News: FDA Okays Byetta Plus Insulin Glargine - in Public Health & Policy, FDA General from MedPage Today
medpagetoday.com — “WASHINGTON -- The FDA has approved a new indication for the type 2 diabetes drug exenatide (Byetta) as an add-on therapy with insulin glargine, diet, and exercise for adult patients.” View full resource at medpagetoday.com
Most Recently Shared on October 20, 2011 at 6:35 pm By:
FDA okays Byetta plus insulin glargine: http://t.co/SjJfiocG
New Indication for Exenatide : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on October 20, 2011 at 2:18 pm By:
Bob Finn - Medical News Net Health News
FDA: Exenatide (Byetta) approved for adults with type 2 diabetes as an add-on therapy to insulin glargine. http://t.co/DKg62KJu
FDA approves expanded access to RX Acculink stent for clogged neck artery treatment
news-medical.net — “The U.S. Food and Drug Administration today approved an expanded indication that will allow a new group of patients at risk of stroke due to clogged neck arteries to be treated with the RX Acculink carotid stent.” View full resource at news-medical.net
Most Recently Shared on May 7, 2011 at 9:39 am By:
FDA approves expanded access to RX Acculink stent for clogged neck artery treatment: The U.S. Food and Drug Admi... http://bit.ly/lulxVT
FDA Expands Approved Use For Carotid Stent
medicalnewstoday.com — “The U.S. Food and Drug Administration today approved an expanded indication that will allow a new group of patients at risk of stroke due to clogged neck arteries to be treated with the RX Acculin” View full resource at medicalnewstoday.com
Most Recently Shared on May 6, 2011 at 5:05 pm By:
MNT Drug Approvals Health News
FDA Expands Approved Use For Carotid Stent http://mnt.to/3Vxj #regulatory
FDA Approval Of Menactra Meningococcal Conjugate Vaccine Indication For Infants Announced By Sanofi Pasteur
medicalnewstoday.com — “Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has granted licensure to expand th” View full resource at medicalnewstoday.com
Most Recently Shared on April 25, 2011 at 4:05 pm By:
FDA Approval Of Menactra Meningococcal Conjugate Vaccine Indication For Infants Announced By Sanofi Pasteur http://mnt.to/3TYW
FDA approves Sanofi Pasteur's meningococcal vaccine
news-medical.net — “Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra, to include a two-dose schedule for infants and children 9 months through 23 months of age.” View full resource at news-medical.net
Most Recently Shared on April 25, 2011 at 11:44 am By:
Meningitis News: FDA approves Sanofi Pasteur's meningococcal vaccine: Sanofi Pasteur, the vaccines division of t... http://bit.ly/eCrvvc
Boston Scientific Receives Exclusive Expanded Indication For Its CRT-Ds
medicalnewstoday.com — “oston Scientific Corporation (NYSE: BSX) announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its cardiac resynchronization therapy defibrillators (C” View full resource at medicalnewstoday.com
Most Recently Shared on September 17, 2010 at 2:05 pm By:
MedicalNewsToday: Boston Scientific Receives Exclusive Expanded Indication For Its CRT-Ds http://bit.ly/dsVp9q Full http://bit.ly/cn9ys0
Merck Receives Approval from FDA for Expanded Indications for Atypical Antipsychotic Medication Saphris (asenapine) Sublingual Tablets
drugs.com — “Saphris (asenapine) is used for the treatment of schizophrenia and bipolar I disorder. Saphris information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on September 14, 2010 at 1:14 am By:
Drugs and Devices OW OW Health
Merck Receives Approval from FDA for Expanded Indications for Atypical Antipsychotic Medication Saphris (asen... http://bit.ly/cBfzbG #drug
Merck Receives Approval From FDA For Expanded Indications For
pharmaceuticalonline.com — “Merck Receives Approval From FDA For Expanded Indications For Atypical Antipsychotic Medication SAPHRIS (Asenapine) Sublingual Tablets - Merck” View full resource at pharmaceuticalonline.com
Most Recently Shared on September 9, 2010 at 3:21 pm By:
Peter H Brown Doctor and Psychologist
Merck Receives Approval From FDA For Expanded Indications For http://bit.ly/b9iass #psychosis #schizo
PharmaLive: Merck Receives Approval from FDA for Expanded Indications for Atypical Antipsychotic Medication Saphris (asenapine) Sublingual Tablets
pharmalive.com — “PharmaLive: Merck Receives Approval from FDA for Expanded Indications for Atypical Antipsychotic Medication Saphris (asenapine) Sublingual Tablets” View full resource at pharmalive.com
Most Recently Shared on September 7, 2010 at 3:17 pm By:
Peter H Brown Doctor and Psychologist
Merck Receives Approval from FDA for Expanded Indications for Atypical ... http://bit.ly/cmmHON #bipolar
Merck News Item
merck.com — “Merck News Item” View full resource at merck.com
Most Recently Shared on September 7, 2010 at 2:46 pm By:
eyeonfda Pharma and Health Lawyer
Merck Gets FDA Approval 4 Expanded Indications for Atypical Antipsychotic Medication SAPHRIS® (asenapine) - http://ow.ly/2Axqb
US FDA committee recommends expanded approval for Eli Lilly's Cymbalta to a broader pain population - International
pharmabiz.com — “The US Food and Drug Administration (FDA) Anaesthetic and Life Support Drugs Advisory Committee voted 8-6 in favour of expanding the pain indications for Eli Lilly and Company's” View full resource at pharmabiz.com
Most Recently Shared on August 21, 2010 at 5:14 pm By:
US FDA committee recommends expanded approval for Eli Lilly's Cymbalta to a broader pain population: The US Food a... http://bit.ly/d2LGKu
FDA Panel Roundly Rejects CNS Drug for Fibromyalgia - QualityPoint Technologies
qualitypointtech.net — “BETHESDA, Md. (MedPage Today) -- A federal advisory panel has voted 20-2 to recommend that the FDA not grant approval for an expanded indication for sodium oxybate (Xyrem) -- also known as GHB -- to treat fibromyalgia.” View full resource at qualitypointtech.net
Most Recently Shared on August 20, 2010 at 11:57 pm By:
FDA Panel Roundly Rejects CNS Drug for Fibromyalgia: BETHESDA, Md. (MedPage Today) -- A federal advisory panel has... http://bit.ly/beJXWE
Cymbalta (Duloxetine HCl) Approved By FDA Advisory Committee For Expanded Pain Indications - QualityPoint Technologies
qualitypointtech.net — “The Anesthetic and Life Support Drugs Advisory Committee which advises the FDA on whether to approve new drugs or alter their indications, has voted 8-6 in favor of expanding pain indications for Cymbalta (duloxetine HCl). The Committee's decision is not final - the FDA has to decide - however, the FDA usually goes along with what the Committee recommends. The Advisory Committee recommended the expanded use of Cymbalta for the treatment of chronic knee and lower back pain...” View full resource at qualitypointtech.net
Most Recently Shared on August 20, 2010 at 1:18 pm By:
Cymbalta (Duloxetine HCl) Approved By FDA Advisory Committee For Expanded Pain Indications: The Anesthetic and Lif... http://bit.ly/cEcF29
Advertisement
